Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrea Neisser‐Svae
Observed names:
A. Neisser-Svae,
A. Neisser‐Svae,
Andrea Neisser-Svae
Institution:
Octapharma (Austria)
Observed institutions:
Octapharma (Switzerland),
Octapharma (Austria),
Octapharma (United States)
OpenAlex ID:
A5057190372
Biochemical quality of the pharmaceutically licensed plasma OctaplasLG® after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time
2009
·
A. Heger
, T.‐E. Svae
, et al.
·
Vox Sanguinis
·
65
Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate®)
2006
·
M. Stadler
, G. Gruber
, et al.
·
Biologicals
·
50
Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)‐treated plasma OctaplasLG®
2009
·
A. Neisser‐Svae
, A. Bailey
, et al.
·
Vox Sanguinis
·
43
Five‐day stability of thawed plasma: solvent/detergent‐treated plasma comparable with fresh‐frozen plasma and plasma frozen within 24 hours
2015
·
Andrea Neisser‐Svae
, Laurenz Trawnicek
, et al.
·
Transfusion
·
34
PDF
Differences in the biochemical composition of three plasma derived human fibrinogen concentrates
2021
·
Andrea Neisser-Svae
, Oliver Hegener
, et al.
·
Thrombosis Research
·
33
PDF
Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment
2008
·
Tor-Einar Svae
, Andrea Neisser-Svae
, et al.
·
Transfusion and Apheresis Science
·
17
Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing – results from animal bioassay studies
2011
·
A. Heger
, A. Bailey
, et al.
·
Vox Sanguinis
·
10
Solvent/Detergent Plasma
2012
·
Tor‐Einar Svae
, Andrea Heger
, et al.
·
Wiley eBooks
·
9
Comment on: Addendum to the British Committee for Standards in Haematology ( BCSH ): Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant, 2004 (Br. J Haematol 2004,126,11‐28)
2016
·
Andrea Neisser‐Svae
, Andrea Heger
·
British Journal of Haematology
·
8
PDF
Thrombin generation potential and clot‐forming capacity of thawed fresh‐frozen plasma, plasma frozen within 24 h and solvent/detergent‐treated plasma (octaplas LG ®), during 5‐day storage at 1–6°C
2018
·
A. Heger
, A. Neisser‐Svae
, et al.
·
Vox Sanguinis
·
6
The state of the art of removal of prion proteins in SD-FFP, by specific prion affinity chromatography and its impact on the hemostatic characteristics of the product
2015
·
Andrea Neisser-Svae
, Jerard Seghatchian
·
Transfusion and Apheresis Science
·
5
PDF
On “Composition, Quality Control, and Labeling of Plasma-Derived Products for the Treatment of von Willebrand Disease” (Semin Thromb Hemost 2006;32: 529-536)
2007
·
Tor-Einar Svae
, Lothar Biesert
, et al.
·
Seminars in Thrombosis and Hemostasis
·
4
Two solvent/detergent‐treated plasma products with a different biochemical profile
2016
·
A. Neisser‐Svae
, A. Heger
·
ISBT Science Series
·
3
PDF
Viral Safety of a Novel Von Willebrand Factor and Factor VIII Concentrate (Wilate®): Virus Inactivation Capacities of Optimised Solvent/Detergent and Terminal Dry-Heat Treatment (PermaHeat).
2005
·
Lothar Biesert
, Haryadi Suhartono
, et al.
·
Blood
·
1
Protein-Biochemical Characterisation of Wilate®: Determination of the Upper Residual Moisture Limit during Terminal Dry-Heat Treatment (PermaHeat).
2005
·
Christoph Kannicht
, Monika Stadler
, et al.
·
Blood
Characterisation of the Novel, High Purity, Double Virus Inactivated Von Willebrand Factor and Factor VIII Concentrate Wilate®.
2005
·
Monika Stadler
, Gerhard Gruber
, et al.
·
Blood
Show more works
View as search
Works count:
16
Citation count:
288
H-index:
8
I10-index:
7
Year
Topic
Type